Otsuka

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

EU approves Otsuka's long-acting HAE drug Dawnzera

An EMA nod for Otsuka's Dawnzera offers EU patients with HAE a drug that can be self-administered by patients with up to eight weeks between doses.

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

App to support people with depression launches in GB

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

WhatsApp lands Moderna in hot water with PMCPA

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), with Novo Nordisk, Otsuka, AstraZeneca, and Daiichi Sankyo also fo

11 high-impact drugs to look out for in 2026

EU approves Otsuka's long-acting HAE drug Dawnzera

Otsuka joins IgAN market with Voyxact approval in US

App to support people with depression launches in GB

Otsuka, Vera stake their claims to IgAN treatment

WhatsApp lands Moderna in hot water with PMCPA

Doctors dismayed by report of NHS AI proposal

Discover a new era of healthcare panel engagement: Grounded ...

Otsuka

Editor's Picks